Anti-CD14 Antibody, Biotin-Labeled

CD14 (Cluster of Differentiation-14) is a surface antigen expressed predominantly by monocytes and macrophages. It is considered a patterned recognition receptor (PRR), which recognizes pathogen markers. Specifically, CD14 acts as a co-receptor for lipopolysaccharides (LPS) found in the outer membrane of gram-negative bacteria. Through this interaction, CD14 supports initiation of the innate immune response during bacterial infection. CD14 also contributes toward immune responses to viral pathogens such as human respiratory syncytial virus (RSV) and may amplify the inflammatory response observed in severe cases of SARS-CoV-2 infection (COVID-19) . Monoclonal antibodies against CD14 are currently undergoing clinical trial as a candidate treatment to limit severe inflammatory responses common in patients hospitalized with COVID-19.

This protein is enzymatically biotinylated using Avi-Tag™ technology. Biotinylation confirmed to be ≥90%.For more information on enzymatic biotinylation, please see ourTech Note.